Cargando…

Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using Metabolomics

Alzheimer’s Disease (AD) currently affects more than 5 million Americans, with numbers expected to grow dramatically as the population ages. The pathophysiological changes in AD patients begin decades before the onset of dementia, highlighting the urgent need for the development of early diagnostic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trushina, Eugenia, Dutta, Tumpa, Persson, Xuan-Mai T., Mielke, Michelle M., Petersen, Ronald C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658985/ https://www.ncbi.nlm.nih.gov/pubmed/23700429 http://dx.doi.org/10.1371/journal.pone.0063644

Ejemplares similares

Application of Metabolomics in Alzheimer’s Disease
por: Wilkins, Jordan Maximillian, et al.
Publicado: (2018)

Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer’s disease (from the Nakayama Study)
por: Ozaki, Tomoki, et al.
Publicado: (2022)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimer’s Disease
por: Pereira Vatanabe, Izabela, et al.
Publicado: (2021)

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
por: Papaliagkas, Vasileios, et al.
Publicado: (2023)

Metabolomic profiling of CSF and blood serum elucidates general and sex-specific patterns for mild cognitive impairment and Alzheimer’s disease patients
por: Berezhnoy, Georgy, et al.
Publicado: (2023)

Concordance of Changes in Metabolic Pathways Based on Plasma Metabolomics and Skeletal Muscle Transcriptomics in Type 1 Diabetes
por: Dutta, Tumpa, et al.
Publicado: (2012)

CSF contamination contributes to apparent microstructural alterations in mild cognitive impairment
por: Berlot, Rok, et al.
Publicado: (2014)

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures
por: Mielke, Michelle M., et al.
Publicado: (2019)

Alzheimer's disease mechanisms in peripheral cells: Promises and challenges
por: Trushina, Eugenia
Publicado: (2019)

Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
por: Tönnies, Eric, et al.
Publicado: (2017)

Type-2-Diabetes Alters CSF but Not Plasma Metabolomic and AD Risk Profiles in Vervet Monkeys
por: Kavanagh, Kylie, et al.
Publicado: (2019)

Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment
por: Chan, Carol K., et al.
Publicado: (2020)

The Effects of CSF Neurogranin and APOE ε4 on Cognition and Neuropathology in Mild Cognitive Impairment and Alzheimer’s Disease
por: Fan, Yulan, et al.
Publicado: (2021)

Association of CSF GAP-43 and APOE ε4 with Cognition in Mild Cognitive Impairment and Alzheimer’s Disease
por: Zhu, Yueli, et al.
Publicado: (2022)

Blood and CSF chemokines in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis
por: Zhou, Futao, et al.
Publicado: (2023)

Higher baseline levels of CSF inflammation increase risk of incident mild cognitive impairment and Alzheimer's disease dementia
por: Contreras, Joey A., et al.
Publicado: (2022)

Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimer’s Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis
por: Dulewicz, Maciej, et al.
Publicado: (2022)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

Quantity and quality of mental activities and the risk of incident mild cognitive impairment
por: Krell-Roesch, Janina, et al.
Publicado: (2019)

Altered γ-secretase activity in mild cognitive impairment and Alzheimer's disease
por: Kakuda, Nobuto, et al.
Publicado: (2012)

Selection of subjects for clinical trials in Alzheimer’s disease and mild cognitive impairment with machine learning analysis of MRI and CSF biomarkers
por: Escudero, Javier, et al.
Publicado: (2011)

Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease
por: Jiang, Hong, et al.
Publicado: (2011)

Visit-to-Visit Blood Pressure Variability and CSF Alzheimer Disease Biomarkers in Cognitively Unimpaired and Mildly Impaired Older Adults
por: Sible, Isabel J., et al.
Publicado: (2022)

Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers
por: Grambaite, Ramune, et al.
Publicado: (2013)

Association Analysis of Peripheral and CSF Biomarkers in Late Mild Cognitive Impairment
por: Zhang, Tao, et al.
Publicado: (2020)

Mitochondrial complex I as a therapeutic target for Alzheimer's disease
por: Trushina, Eugenia, et al.
Publicado: (2022)

CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment
por: Karami, Azadeh, et al.
Publicado: (2021)

Advances in Recapitulating Alzheimer’s Disease Phenotypes Using Human Induced Pluripotent Stem Cell-Based In Vitro Models
por: Hasan, Md Fayad, et al.
Publicado: (2022)

Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ε4 Allele
por: Roberts, Rosebud O., et al.
Publicado: (2015)

Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease
por: Mattsson, Niklas, et al.
Publicado: (2013)

EEG alterations during wake and sleep in mild cognitive impairment and Alzheimer's disease
por: D'Atri, Aurora, et al.
Publicado: (2021)

Altered Functional Connectivity of Basal Ganglia in Mild Cognitive Impairment and Alzheimer’s Disease
por: Xiong, Yu, et al.
Publicado: (2022)

Cerebrospinal Fluid Metabolomics: Pilot Study of Using Metabolomics to Assess Diet and Metabolic Interventions in Alzheimer’s Disease and Mild Cognitive Impairment
por: Hanson, Angela J., et al.
Publicado: (2023)

One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond
por: Dayon, Loïc, et al.
Publicado: (2017)

Untargeted Metabolomic Analysis of Human Plasma Indicates Differentially Affected Polyamine and L-Arginine Metabolism in Mild Cognitive Impairment Subjects Converting to Alzheimer’s Disease
por: Graham, Stewart F., et al.
Publicado: (2015)

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
por: Paolini Paoletti, Federico, et al.
Publicado: (2023)

Writing Impairments in Japanese Patients with Mild Cognitive Impairment and with Mild Alzheimer's Disease
por: Hayashi, Atsuko, et al.
Publicado: (2015)

Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer’s disease
por: Jiang, Xiong, et al.
Publicado: (2021)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b3no1ooa0enbmsj3dacqp8u0r2